Nepicastat

From Self-sufficiency
Revision as of 13:15, 20 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Nepicastat
File:Nepicastat.png
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
CAS number 173997-05-2
PubChem 6367078
ChemSpider 7971947
MeSH Nepicastat
SMILES Script error: No such module "collapsible list".
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula C14H15F2N3S
Molar mass 295.35 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Nepicastat (INN, codenamed SYN117) is an inhibitor of dopamine beta-hydroxylase, an enzyme that catalyzes the conversion of dopamine to norepinephrine.[1]

It has been studied as a possible treatment for congestive heart failure, and appears to be well tolerated as such.[2] As of 2008, clinical trials to assess nepicastat as a treatment for post-traumatic stress disorder (PTSD) and cocaine dependence are recruiting participants.[3][4]

500px

U.S. Patent 5,719,280

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. "Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)". ClinicalTrials.gov. U.S. National Institutes of Health. June 4, 2008.  Retrieved on October 7, 2008.
  4. "Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers". ClinicalTrials.gov. U.S. National Institutes of Health. August 15, 2008.  Retrieved on October 7, 2008.